Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
18 angezeigte Treffer · Seite 1, keine Gesamtzahl für „relugolix“
Suchtreffer
Begriffe & Kennungen
Orgovyx · 4.5 · *: Upon co-administration of azithromycin and relugolix, relugolix exposure increases up to 5-fold were observ
Eintrag öffnenOrgovyx · 4.5 · 11 Relugolix dose Drug dose Change in Change in Recommendation regimen regimen drug AUC0- drug Cmax inf
Eintrag öffnenOrgovyx · 4.5 · 5 Table 1. Effect of co-administered medicinal products on relugolix exposure (Cmax, AUC0- inf) and recommenda
Eintrag öffnenOrgovyx · 4.5 · 9 to 266 days in the phase 3 study, plasma relugolix trough concentrations did not change to a clinically sign
Eintrag öffnenOrgovyx · 4.5 · Based on limited data (n=20) in men who received a 120 mg dose of relugolix and 80 to 160 mg doses of enzaluta
Eintrag öffnenOrgovyx · 4.5 · Co-administration of Orgovyx and oral P-gp inhibitors is not recommended. Relugolix is a P-gp substrate (see s
Eintrag öffnenOrgovyx · 4.5 · Considering that the 360 mg loading dose of relugolix has not been tested, dose separation of the loading dose
Eintrag öffnenOrgovyx · 4.5 · In vitro studies Cytochrome P450 (CYP) enzymes: Relugolix is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C
Eintrag öffnenOrgovyx · 4.5 · Interacting drug dose Relugolix Change in Change in Recommendation regimen dose relugolix relugolix regimen AU
Eintrag öffnenOrgovyx · 4.5 · No clinically significant differences in the pharmacokinetics of relugolix were observed upon co-administratio
Eintrag öffnenOrgovyx · 4.5 · Potential for other medicinal products to affect the exposure to relugolix
Eintrag öffnenOrgovyx · 4.5 · Relugolix is a weak inducer of CYP3A mediated metabolism, and an inhibitor of BCRP and P-gp in vitro. Effect o
Eintrag öffnenOrgovyx · 4.5 · Table 2. Effect of relugolix on exposure (Cmax, AUC0-inf) of co-administered medicinal products and recommenda
Eintrag öffnenOrgovyx · 4.5 · Therefore, no dose modifications are recommended for co- administration of relugolix and enzalutamide.
Eintrag öffnenOrgovyx · 4.5 · Transporter systems: Relugolix is not an inhibitor of OATP1B1, OATP1B3, OATP2B1, OAT1, OAT3, OCT2, MATE1, MATE
Eintrag öffnenOrgovyx · 4.8 · The most commonly observed adverse reactions during relugolix therapy are physiological effects of testosteron
Eintrag öffnenrelugolix
Eintrag öffnenrelugolix
Eintrag öffnen